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Abstract 
Recent  studies  have  reported  autonomic
dysfunction (AD) in multiple sclerosis (MS),
and bladder and/or bowel dysfunction, ortho-
static hypotension, and cardiac adaptation dis-
orders have been observed in a wide range of
patients  (15-80%).  The  primary  aim  of  this
study is to investigate the frequency and asso-
ciation of AD in MS patients, assessed by sym-
pathetic skin response (SSR) and a symptoms
questionnaire.  The  secondary  aims  are  to
study the association of AD and disease dis-
ability assessed by expanded disability status
scale (EDSS), as well as disease duration. One
hundred  clinically  definite  MS  (CDMS)
patients were evaluated for autonomic nervous
system (ANS) dysfunction by use of an auto-
nomic symptoms questionnaire and SSR test-
ing. The relationship between these methods,
AD  and  disease-related  parameters,  such  as
the  expanded  disability  status  scale  (EDSS)
and disease duration were all evaluated. Sixty-
five per cent of the patients presented with AD
and 29% of these patients had abnormal SSR
results.  MS  patients  with  high  EDSS  values
(EDSS>4) and longer disease duration were
more  likely  to  have  ANS  dysfunction
(p<0.0001).  ANS  dysfunction  is  not  uncom-
mon in CDMS patients and thus non-invasive
investigations of AD are warranted to optimize
AD evaluation and disease management.
Introduction
Multiple sclerosis (MS) is an inflammatory
demyelinating disease of the central nervous
system with heterogeneous neurological pres-
entation. Recent studies have reported auto-
nomic  dysfunction  (AD)  in  a  wide  range  of
patients  with  MS  that  might  present  with
abnormalities in the regulation of the cardio-
vascular system, sleep disturbances and tem-
perature  regulation  problems  (15-80%).  The
pathophysiology behind AD remains under dis-
pute but demyelinating lesions located adja-
cent  to  the  hypothalamus  involving  fornix,
anterior  commissure,  internal  capsule  and
optic system might be the basis for autonomic
and endocrine malfunction in MS patients.
1,2
AD should be considered as one of the crucial
components that have an impact on the quali-
ty of life outcomes in MS patients and patients
need to be questioned for AD. The diagnostic
utility  of  laboratory  tests  including  electro-
physiological evaluations for assessing AD in
MS  patients  has  been  established  and  addi-
tionally some studies have suggested the use
of some self-completed questionnaires on the
symptoms of patients with AD.
3-6 The primary
aim of this study is to investigate the frequen-
cy of AD in MS patients, assessed by sympa-
thetic skin response (SSR) and a symptoms
questionnaire,  and  look  for  an  association
between these methods. The secondary aims
of this study are to study the association of AD
evaluated by both SSR and symptoms question-
naire, and disability assessed by expanded dis-
ability status scale (EDSS), as well as to study
the association between AD and disease dura-
tion.
Patients and Methods
Patient ascertainment
This  prospective  study  was  carried  out  in
the MS Clinic of the Department of Neurology,
Okmeydani  Training  and  Research  Hospital.
After ethical committee approval, one hundred
clinically definite MS patients were randomly
selected from a larger cohort of patients who
were  followed  in  the  MS  outpatient  clinic.
7
Although McDonald criteria is the latest and
commonly  accepted  diagnostic  criteria,  we
used  Poser  criteria  to  establish  consistency
among the cohort because some patients who
were enrolled into the study had long disease
duration and Poser criteria had been utilized
for their diagnosis. The selection was blinded
to  clinical  complaints  relating  to  autonomic
dysfunction to avoid selection bias. In terms of
clinical phenotypes, patients with a relapsing
remitting disease course or a secondary pro-
gressive disease course were enrolled into the
study.  Patients  did  not  have  clinically  active
disease  and  did  not  receive  corticosteroid
treatment within eight weeks of enrollment.
Patients were excluded if comorbidities were
present that could interfere with evaluation of
autonomic nervous system (ANS) dysfunction
(e.g. cardiac disease, alcohol dependency, col-
lagen disease, diabetes mellitus, renal failure,
liver  failure,  and  peripheral  neuropathy).
Patients  were  asked  to  stop  anticholinergic
medications 48 hours before testing, and drugs
such  as  antidepressants,  sympathomimetics,
parasympathomimetics, and ß blockers were
discontinued  24  hours  prior  to  testing.  The
purpose of the test was fully explained to the
patients and informed consent was obtained.
Patient evaluation
All  patients  were  evaluated  by  an  experi-
enced  neurologist  by  routine  neurological
examination, including assessment of EDSS.
This grading system is considered to be the
most practical clinical measure of MS disease
activity and is accepted as the primary clinical
outcome measure in most MS clinical trials.
8
Because of possible inter-observer variability
of EDSS scoring, disability was determined by
a single experienced neurologist. 
During  the  neurological  evaluation,  the
same  investigator  provided    patients  with  a
standard questionnaire for the clinical investi-
gation of ANS involvement. Due to the lack of
an available validated questionnaire that was
translated  into  Turkish,  we  developed  an
inventory of self-reported measures of symp-
toms relating to autonomic dysfunction based
on  recent  literature.
9-13 The  questionnaire
included symptoms of autonomic dysfunction:
orthostatic dizziness, palpitations; vasa-secre-
tory motor symptoms (pallor and coldness of
skin, increased or lack of sweating in extremi-
ties, increased salivation or dryness of mouth
or  eyes);  post-prandial  symptoms;  bladder
problems, bowel problems (constipation); and
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[Neurology International 2009; 1:e5] [page 15]sexual problems (erection and ejaculation dif-
ficulties,  loss  of  libido/orgasm)  (see
Appendix).    The  scoring  from  the  question-
naire was based on answers “yes” (score: 1)
and “no” (score: 0) and a total was calculated
for each patient. Higher scores indicated more
or worse symptoms.  
Autonomic nervous system
assessment, sympathetic skin
response 
Patients were instructed to lie down in a
comfortable and relaxed position in a quiet,
well-lit and air-conditioned room. SSRs were
recorded  between  the  hours  of  09:00  and
13:00.  Five  random  non-painful  electrical
stimuli  were  administered  to  the  median
nerve  at  the  wrist  (110  mV,  0.1  s).  Stimuli
were  applied  at  irregular  intervals,  but  the
delay between two stimuli was always greater
than 30 seconds. SSR testing was performed
by applying standard surface EMG electrodes
(Nihon Kohden EMG) to the palm and the dor-
sum of the hands and feet with an amplifier
gain of 0.1-2 mV and filter. The amplitude and
latency of each response were not assessed as
they  varied  greatly  on  consecutive  stimula-
tions. The expected normal response to the
electric stimulus is a wave formation with a
long duration and low amplitude due to the
galvanic sympathetic response because of an
instant change in the electric potential of the
skin of the palms and feet. When electric stim-
ulus is applied, it is conveyed to the sympa-
thetic  centers  through  the  somatosensory
pathway (afferent part of the arch). The sym-
pathetic centers, namely the rear hypothala-
mus and the mesencephalic reticular forma-
tion,  process  the  peripheral  stimulus  and
through efferent sympathetic fibers stimulate
the sudomotor glands.
5,6,14,15 SSR is an interseg-
mental  multisynaptic  somato-sympathetic
reflex and its amplitude varies greatly within
and between subjects, making the amplitude
or latencies unreliable parameters for the SSR.
Moreover,  the  circadian  variability  of  SSR
latencies has been demonstrated in normative
studies. Therefore, the result of the test was
considered abnormal if no consistent voltage
change and wave formation was observed in at
least  one  extremity  after  the  application  of
electrical stimuli (100 mV, 0.1 s). The results
were compared with the electrophysiology lab-
oratory normative database results.
Statistical analysis
Descriptive  statistics  were  applied  to  the
demographic  features  of  the  cohort.  Group
comparisons were evaluated by one-way analy-
sis. Wilcoxon’s rank test was applied for con-
tinuous variables and Kruskal-Wallis rank test
was used for ordinal and continuous variables.
Tests were two-sided and a p<0.05 was consid-
ered statistically significant.
Results
We  identified  100  clinically  definite  MS
patients (68 females, 68%), the mean age of
the patient group was 36±9 years. From the
patient group, 65 (65%) patients were assessed
to present with autonomic symptoms evaluated
by the standard questionnaire (Table 1). Thirty-
five (35%) patients did not have any autonom-
ic dysfunctions and only 14 (14%) patients pre-
sented with one autonomic dysfunction. SSR
evaluation  revealed  that  no  wave  formation
could be elicited in 29 (29%) patients and was,
therefore,  considered  abnormal.  These  29
patients  were  among  the  group  who  had  at
least one AD evaluated by the questionnaire
and none of the patients without any autonom-
ic symptoms had SSR abnormalities. A statisti-
cally  significant  association  was  observed
between  AD  evaluated  by  the  questionnaire
and  SSR  results  (p<0.0001).  Seventy-seven
(77%)  patients  presented  relapsing-remitting
form of MS, and 23 (23%) patients presented as
secondary  progressive  MS.  The  mean  EDSS
score  for  the  patient  group  was  3±1.8.  The
patients were grouped into 2 categories accord-
ing to EDSS scores as follows: 1) EDSS < 4.67
(67%)  patients  and  2)  EDSS  >4.33  (33%)
patients. A statistically significant association
was observed between EDSS categories and AD
results by the questionnaire (p<0.0001). The
mean disease duration was 7.4±5.5 (range, 1-
18 years) and the disease duration was statisti-
cally  correlated  with  autonomic  impairment
(p<0.0001) (Table 2).
Conclusions
SSR findings seem to reflect axonal conduc-
tion  blockage  due  to  brain  and  spinal  cord
demyelination and,  in addition to MS lesions
effecting hypothalamus, inflammatory media-
tors are also considered to have an impact on
the control of autonomic and endocrine func-
tioning in MS patients.
2
Various studies have evaluated the associa-
tion of disease disability, disease duration and
AD evaluated by SS.
16-22 Our study aims to carry
this further with a large sample size and eval-
Article
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Table 1. Demographic and clinical characteristics of patients.
Gender f:m 2:1
Age (years)  36±9
Dd (years)  7.4±5.5
Dc (%)
Rrms  77 (77)
Spms  23 (23)
Edss  3±1.8
Ans symptoms (%) 64 (64)
Bladder problems  64 (64)
Bowel problems  50 (50)
Sexual problems  27 (27)
Cvs problems/orthostatic hypotension  24 (24)
Thermic problems  24 (24)
Gastric problems  24 (24)
Values are expressed as mean with standard deviation (sd). Dd; disease duration, dc; disease course, rrms; relapsing remitting ms,
spms; secondary progressive ms, edss; expanded disability status scale, ans; autonomic nervous system, cvs; cardiovascular system.
Table 2. Distribution of autonomic dysfunction among the patient group.
EDSS <4 (n=67) EDSS >4 (n= 33) p
DD 4.3±3.1 13.7±3.5  <0.0001
SSR abnormality (%)  6 (9) 23 (70) <0.0001
Bladder problems (%)  33 (50) 31 (94) <0.0001
Bowel problems (%)  19 (28) 31 (94) <0.0001
CVS problems (%)  2 (3) 22 (67)  <0.0001
Sexual problems (%) 1 (1)  26 (79) <0.0001
Values are expressed as mean with standard deviation and p value. EDSS; expanded disability status scale, DD; disease duration, SSR;
sympathetic skin reaction,. Group comparisons were evaluated by one-way analysis. Tests applied were two-sided; Wilcoxon’s rank
test was applied for continuous variables and Kruskal-Wallis rank test was used for ordinal and continuous variables.uate autonomic system involvement not only
by SSR but also by a symptoms questionnaire.
Our findings suggest that there is a significant
association between ANS dysfunction evaluat-
ed by the questionnaire and the electrophysio-
logical evaluation by SSR, as well as disease
duration. Disease duration in addition to AD
also most likely correlates with clinical course.
EDSS is a grading system widely accepted and
used during the follow-up of MS patients to
assess the level of disease progression evaluat-
ing  motor  and  sensory  functions  with  no
emphasis on autonomic involvement. Recent
studies  including  additional  autonomic  tests
have  shown  that  when  a  multidisciplinary
method including evaluation of multiple auto-
nomic system parameters is utilized, there is a
higher percentage of AD abnormality among
MS patients. Here we aimed to capture the AD
evaluating a self-assessment method and com-
bining  the  questionnaire  with  an  available,
practical  technique.  SSR  testing  has  been
reported to be an effective method of assessing
sympathetic  sudomotor  outflow  disturbances
in MS, providing a valuable ancillary method to
current  electrophysiological  procedures.
5,14
Recent electrophysiological studies found that
SSR  correlated  with  the  degree  of  disability
evaluated by EDSS and De Seze et al. recently
reported  that  AD  was  correlated  with  spinal
cord  cross-sectional  area  reduction  but  not
with spinal cord hyperintensities.
5 This study
confirms that the frequency of AD in MS, espe-
cially in primary progressive forms, has until
now  been  underestimated.  Furthermore,  AD
appears to be more closely related to axonal
loss, as demonstrated by spinal cord atrophy,
than to demyelinating lesions. In addition, this
study found SSR abnormalities in 48% of pro-
gressive MS patients when compared to the
relapsing remitting subgroup (30%). In anoth-
er  study  by  McDougall  et  al.,  no  significant
association was observed between SSR and MS
severity  suggesting  that  cardiovascular  and
sudomotor  autonomic  abnormalities  in  MS
patients are likely to be due to plaques distrib-
uted throughout the brainstem and spinal cord
affecting anatomically widespread autonomic
regulatory areas and their connections.
16
SSR is a beneficial test for sympathetic tract
lesions and correlates with the degree of dis-
ability and AD in MS patients.
5,17,22 Recent stud-
ies also described questionnaires that meas-
ure autonomic symptoms and presented evi-
dence for validity.
9-13 This paper also aims to
raise the need for a validated ANS dysfunction
questionnaire for MS patients and clinicians
should be encouraged to use an available ques-
tionnaire.
The correlation between SSR testing and a
questionnaire suggests that a questionnaire
might be an available and simple surrogate
tool  in  assessing  autonomic  symptoms  in
clinical  trials  and  epidemiological  studies,
especially when SSR testing is not available.
Autonomic testing seems to be supportive to
detect  eventual  subclinical  changes  in  MS
and  should  be  taken  into  consideration  in
outcome measures. Further long-term follow-
up studies combining clinical, electrophysio-
logical and radiological assessments are war-
ranted to clarify means to evaluate AD, the
impacts of multifactorial etiology on MS dis-
ability, and to demonstrate the correlation of
autonomic  dysfunction  with  other  disease-
related parameters.
Appendix: questionnaire on clinical
autonomic dysfunction
1. Manifestations  occurring  after  changing
position (yes/no): In the past year, have
you  frequently  (at  least  once  a  week)
experienced one or more symptoms, such
as palpitations, dizziness, blurred vision or
feeling  of  weakness,  after  standing  up
from a sitting or lying down position?
2. Skin manifestations (at least one abnor-
mal  finding)  (yes/no):  In  the  past  year,
have you noticed frequent (at least once a
week) changes in skin color, such as red,
white or purple? Cutaneous abnormalities
at examination?
3. Thermic dysfunctions (at least one abnor-
mal  finding)  (yes/no):  In  the  past  year
have you frequently (at least once a week)
experienced  hot  or  cold  limbs?  Thermic
modifications  found  by  the  examiner?
Thermic  perception  abnormalities  com-
paring hot and cold stimulations?
4. Sphincter dysfunction (at least one abnor-
mal  finding)  (yes/no):  In  the  past  year,
have  you  frequently  (at  least  once  a
month) lost control of your bladder func-
tion?  In  the  past  year,  have  you  experi-
enced  difficulty  in  completely  emptying
your bladder? In the past year, have you
frequently (at least once a month) been
constipated?
5. Sexual dysfunction (at least one abnormal
finding) (yes/no): In the past year, have
you frequently (at least once a month) had
problems  with  ejaculation?  In  the  past
year,  have  you  experienced  difficulty  in
ejaculation?
6. Gastroparesis (at least one abnormal find-
ing) (yes/no): In the past year, have you
frequently (at least once a month) experi-
enced  nausea and vomiting after a meal?
In  the  past  year,  have  you  experienced
feeling full early when eating? In the past
year, have you frequently (at least once a
month) had abdominal bloating and/or dis-
comfort after a meal?
4,6
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